The Economics of Biologic Drugs Alex Brill and Benedic N. Ippolito | Health Affairs Blog The market for biologic drugs in the United States is large and growing. Total US biologic sales in 2018 is estimated to have been $125 billion, an increase of 50 percent since...
Debate Over Whether Biologics Constitute Natural Monopolies Continues Allison Inserro | The Center for Biosimilars “Peter B. Bach, MD, a well-known critic of high drug prices, along with Jennifer A. Ohn, MPH, Preston Atteberry, MD, and Mark Trusheim, MSc, first...
Observable Flaws in CMS’s Dialysis Star-Rating System and a Proposed Alternative Alex Brill | Bloomberg BNA In January 2015, CMS launched a star-rating system for U.S. dialysis facilities. This article analyzes nearly 6,000 U.S. dialysis facilities and explores...
